Viatris Innovation Gmbh
Clinical trials sponsored by Viatris Innovation Gmbh, explained in plain language.
-
Could a quick shot at home stop a heart attack in its tracks?
Disease control ENROLLING_BY_INVITATIONThis study tests a drug called selatogrel that people can inject themselves under the skin. The goal is to see if it can prevent death or reduce the severity of a heart attack in 25,000 adults who recently had one and have other heart risks. Participants are randomly assigned to …
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated May 26, 2026 09:03 UTC
-
New hope for lupus patients: phase 3 trial of cenerimod launches
Disease control OngoingThis study tests whether adding cenerimod to standard lupus treatments can better control symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. The goal is to see if cenerimo…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New lupus drug shows promise in major trial
Disease control OngoingThis study tests whether adding cenerimod to standard lupus treatments can better control symptoms in adults with moderate-to-severe lupus. About 451 participants will receive either cenerimod or a placebo for 12 months. The goal is to see if cenerimod reduces disease activity wi…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New lupus drug tested for Long-Term safety in 680 patients
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 680 participants who completed a previous year-long study will take cenerimod on top of their usual lupus medications for up to 3 years. Researchers w…
Phase: PHASE3 • Sponsor: Viatris Innovation GmbH • Aim: Disease control
Last updated May 20, 2026 11:55 UTC